FACTS ABOUT NEW ADVANCEMENTS IN BRD4 INHIBITION THERAPY ABBV-744 REVEALED

In Phase C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, participants will get ABBV-744 and ruxolitinib. Contributors will receive treatment right up until illness progression or maybe the participants are not able to tolerate the study drugs.For all circulation cytometry experiments, 10,000 cells for each replicate were analy